Literature DB >> 30662020

Diagnosis and Management of Statin Intolerance.

Rodrigo Alonso1, Ada Cuevas1, Alberto Cafferata2.   

Abstract

Statins are the main treatment for hypercholesterolemia and the cornerstone of atherosclerotic cardiovascular disease prevention. Many patients taking statins report muscle-related symptoms, one of the most important causes of statin treatment discontinuation, which is associated with an increased risk of cardiovascular events. Therefore, it is important to identify patients who are truly statin intolerant to avoid unnecessary discontinuation of this beneficial treatment. Some studies indicate that not all muscle complaints are caused by statins, and most patients can tolerate a statin upon re-challenge, down-titration of dose, or switching to another statin. In this paper, we review the definitions of statin intolerance and approaches to reducing cardiovascular risk among individuals reporting statin-associated muscle symptoms.

Entities:  

Keywords:  Cardiovascular disease; Myalgia; Myopathy; Statin intolerance; Statins

Mesh:

Substances:

Year:  2019        PMID: 30662020      PMCID: PMC6402887          DOI: 10.5551/jat.RV17030

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  18 in total

Review 1.  Therapeutic pipeline in nonalcoholic steatohepatitis.

Authors:  Raj Vuppalanchi; Mazen Noureddin; Naim Alkhouri; Arun J Sanyal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-10       Impact factor: 46.802

Review 2.  PCSK9 Antibody-based Treatment Strategies for Patients With Statin Intolerance.

Authors:  Errika Voutyritsa; Christos Damaskos; Paraskevi Farmaki; Georgios Kyriakos; Evangelos Diamantis; Lourdes Victoria Quiles-SÁnchez; Anna Garmpi; Nikolaos Garmpis; Alexandros Patsouras; Athanasia Stelianidi; Spyridon Savvanis
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

Review 3.  SAMSON and the Nocebo Effect: Management of Statin Intolerance.

Authors:  Amrita Krishnamurthy; Corey Bradley; Rebecca Ascunce; Samuel M Kim
Journal:  Curr Cardiol Rep       Date:  2022-06-27       Impact factor: 3.955

Review 4.  Implications of the heterogeneity between guideline recommendations for the use of low dose aspirin in primary prevention of cardiovascular disease.

Authors:  Xiao-Ying Li; Li Li; Sang-Hoon Na; Francesca Santilli; Zhongwei Shi; Michael Blaha
Journal:  Am J Prev Cardiol       Date:  2022-06-06

5.  Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.

Authors:  William A Murphy; Nan Lin; Amy Damask; Gregory G Schwartz; P Gabriel Steg; Michael Szarek; Poulabi Banerjee; Sergio Fazio; Garen Manvelian; Robert Pordy; Alan R Shuldiner; Charles Paulding
Journal:  Circ Genom Precis Med       Date:  2022-05-11

6.  Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial.

Authors:  Shinji Koba; Ikuo Inoue; Marcoli Cyrille; Chen Lu; Hyoe Inomata; Junichiro Shimauchi; Kouji Kajinami
Journal:  J Atheroscler Thromb       Date:  2019-11-21       Impact factor: 4.928

7.  Statin Intolerance-An Asian Perspective.

Authors:  Brian Tomlinson; Paul Chan; Zhong-Min Liu
Journal:  J Atheroscler Thromb       Date:  2019-09-25       Impact factor: 4.928

8.  Understanding the Patient Perception of Statin Experience: A Qualitative Study.

Authors:  Michal Vrablik; Alberico L Catapano; Olov Wiklund; Yi Qian; Pratik Rane; Alyson Grove; Mona L Martin
Journal:  Adv Ther       Date:  2019-09-03       Impact factor: 3.845

9.  Inhibition of the mevalonate pathway improves myocardial fibrosis.

Authors:  Huifeng Xu; Yi Shen; Chenyu Liang; Haifeng Wang; Junling Huang; Pengcheng Xue; Ming Luo
Journal:  Exp Ther Med       Date:  2021-01-18       Impact factor: 2.447

Review 10.  Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components.

Authors:  Richard Myles Turner; Munir Pirmohamed
Journal:  J Clin Med       Date:  2019-12-20       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.